ARTICLE
Received 17 Jan 2014 | Accepted 27 Mar 2014 | Published 7 May 2014
Sara Hultin1, Yujuan Zheng1, Mahdi Mojallal1, Simona Vertuani1, Christian Gentili1, Martial Balland2, Rachel Milloud2, Heinz-Georg Belting3, Markus Affolter3, Christian S.M. Helker4, Ralf H. Adams5, Wiebke Herzog4,5,6, Per Uhlen7, Arindam Majumdar1,* & Lars Holmgren1,*
The assembly of individual endothelial cells into multicellular tubes is a complex morphogenetic event in vascular development. Extracellular matrix cues and cellcell junctional communication are fundamental to tube formation. Together they determine the shape of endothelial cells and the tubular structures that they ultimately form. Little is known regarding how mechanical signals are transmitted between cells to control cell shape changes during morphogenesis. Here we provide evidence that the scaffold protein amotL2 is needed for aortic vessel lumen expansion. Using gene inactivation strategies in zebrash, mouse and endothelial cell culture systems, we show that amotL2 associates to the VE-cadherin adhesion complex where it couples adherens junctions to contractile actin bres. Inactivation of amotL2 dissociates VE-cadherin from cytoskeletal tensile forces that affect endothelial cell shape. We propose that the VE-cadherin/amotL2 complex is responsible for transmitting mechanical force between endothelial cells for the coordination of cellular morphogenesis consistent with aortic lumen expansion and function.
1 Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska University Hospital, 171 76 Stockholm, Sweden. 2 Laboratoire interdisciplinaire de Physique, Universit Joseph Fourier (Grenoble 1), Domaine Universitaire, Bat. E45 140, rue de la physique, Saint Martin dHres Cedex 9 38402 Grenoble, France. 3 Abt. Zellbiologie, Biozentrum/Uni Basel, Klingelbergstrasse 70, CH 4056 Basel, Switzerland. 4 Biological Faculty, University of Muenster, 48149 Muenster, Germany. 5 Max Planck Institute for Molecular Biomedicine, 48149 Muenster, Germany. 6 Cluster of Excellence EXC 1003, Cells in Motion, CiM , 48149 Mnster, Germany. 7 Department of Medical Biochemistry and Biophysics, Karolinska Institute, 171 77 Stockholm, Sweden. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to L.H. (email: [email protected]).
NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications 1
& 2014 Macmillan Publishers Limited. All rights reserved.
DOI: 10.1038/ncomms4743
AmotL2 links VE-cadherin to contractile actin bres necessary for aortic lumen expansion
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743
The genesis of biological tubes is central to the physiology of glandular organs and the vascular circulatory network. In vertebrates, the primary axial blood vessels, the dorsal
aorta (DA) and cardinal vein, are formed through vasculogenesis. During this process, individual mesodermal angioblasts migrate to the embryonic midline and differentiate into endothelial cells. Upon reaching their destination, endothelial cells elongate to form parallel cords followed by the formation of a central lumen allowing for the initiation of circulation14.
Recent investigations have shed light on the molecular mechanisms of aortic lumen formation (reviewed in refs 3,5,6). Model systems recreating endothelial tubulogenesis in vitro have identied the cytoskeleton, apicalbasal polarity as well as cellcell adhesion components as being crucial for lumenization of tubes7. This has been further emphasized by studies of aortic lumen formation by genetic inactivation in mouse where modulators of the cytoskeleton (RASIP1), polarity (beta1 integrin and Par3) and cellcell adhesions (VE-cadherin) all show luminal defects of the DA811. Aortic lumen expansion is synchronized with the onset of cardiac function, which suggests a tight coordination of these signalling pathways with ow-induced morphological changes of endothelial cells during vascular development.
The de novo development of blood vessels in response to morphogenic gradients of growth factors such as VEGF has been extensively studied (reviewed in refs 1,1215). Less is known about how endothelial cells perceive and transmit mechanical forces that modulate vessel shape and function. Extracellular forces are detected by endothelial cells via integrins in focal adhesions that form contact points that transfer tension from the extracellular matrix to the cytoskeleton16. Recent evidence has also shown that actomyosin contractility may be transmitted via adherens junctions17. Exogenous forces applied to cadherin have indicated a mechanical coupling between the cytoplasmic domains of cadherin and the actin cytoskeleton. Furthermore, in vitro measurements of force transmission have revealed that cellcell contact-forming cells sustain endogenous forces that are directed towards the cell junctions1820.
VE-cadherin is a major component of endothelial adherens junctions. It regulates several aspects of endothelial biology including vascular integrity, permeability and blood vessel morphogenesis21. During embryonic vasculogenesis, VE-cadherin is essential for lumenization, and loss of VE-cadherin function resulted in endothelial apicalbasal polarity and cytoskeletal defects2,8,22,23. VE-cadherin regulates the actin network since dynamic remodelling of adherens junctions is closely associated with the appearance of contractile actin bres24. The actin-binding protein a-catenin is considered to be a dedicated mediator between cadherin and the actin cytoskeleton. However, this idea has been revised in favour of a more dynamic model where the a-catenin switch regulates a balance of linear versus branched actin cables depending on its association with ancillary proteins25. Although recent evidence indicates that VE-cadherin play an important role in force transmission, the molecular connection to the actin cytoskeleton remains obscure26.
AmotL2 belongs to the Angiomotin (amot) family of membrane-associated scaffold proteins and contains an amino-terminal glutamine-rich domain coiled-coil repeats and a carboxy-terminal PDZ-binding domain, which together structurally dene the Amot family27. Functional analyses of Amot and amotL1 in mouse and zebrash have demonstrated specic roles in polarity in angiogenic tip cell migration and endothelial cell junction stability, respectively2830. Amot coordinates cell migration and cellular shape by coupling RhoA activity to the leading edge and thereby affecting formation of actin bres31.
In this report, we have addressed how endothelial cells integrate mechanical forces via adherens junctions during the formation of the aortic lumen. We present data suggesting that the amotL2/VE-cadherin junctional complex is part of machinery translating junctional signals to actin cytoskeleton-driven cell shape changes, which are essential for aortic lumen expansion.
ResultsAmotL2 expression in zebrash endothelial cells. The zebrash has emerged as an important model system to analyse the complex development of the primary vessels, the DA and the posterior cardinal vein (PCV) and the expansion of the vascular network by angiogenic sprouting. In zebrash, amotl2 is duplicated with paralogues on chromosomes 6 (amotl2a) and 2 (amotl2b) (Supplementary Fig. 1a). Endothelial expression of amotl2a and 2b was detected by quantitative PCR in uorescence-activated cell sorting Tg(i1a:EGFP)y1 cells from transgenic embryos where EGFP expression is driven by the i1a endothelial specic promoter (Supplementary Fig. 1b). In addition, the amotl2a gene has previously been shown to be expressed in the DA, PCV and intersegmental vessels (ISVs)32.
AmotL2a is required for DA lumen formation. In order to determine whether amotl2 is required for vascular development, we individually targeted amotl2a and amotl2b functions in zebrash using paralogue-specic morpholinos (MO). The effects on the vascular system were monitored using double transgenic embryos, where erythrocytes express dsRed (Tg(gata1:dsRed)sd2) and the vascular endothelial network is visualized via EGFP (Tg(kdrl:EGFP)s843). In agreement with the earlier results, we found that amotl2a depletion resulted in embryos with gastrulation defects32. However, at lower morpholino concentrations, amotl2a MO-injected embryos went through gastrulation properly, but exhibited pericardial oedema starting at 28 h post fertilization (h.p.f.) (Fig. 1a). Knockdown of amotl2b with morpholinos also resulted in pericardial oedema, but did not affect gastrulation (Fig. 1a). Confocal imaging of amotl2a and amotl2b morphant embryos revealed the establishment of both the major axial vessels, PCV and DA, as well as sprouting of ISVs and cranial vessels (Fig. 1a,b and Supplementary Fig. 2a). However, in morphant embryos, dsRed-positive erythrocytes accumulated in the areas of pericardial oedema whereas no circulating cells in the trunk vasculature could be detected (Fig. 1a,b, Supplementary videos 1,2). Simultaneous knockdown of amotl2a and 2b paralogues, hereafter referred to as amotl2 MO, phenocopied the individual morphant phenotypes (Fig. 1a,b). Morpholino knockdown efciency, phenotypic reproducibility and specicity were conrmed in control experiments (Fig. 1ce, Supplementary Fig. 1c,d,e).
In both the individual amotl2a and amotl2b knockdown embryos, and especially in the amotl2 MO double morphants, constrictions within the DA were observed (Fig. 2a). Lumen narrowing was invariably found along the length of the DA, but never in the PCV (95% aortic origin, 0% vein, 5% unknown, n 62) (Fig. 2a). DA lumen defects were not a secondary defect
to the loss of blood circulation based on two observations. First, amotl2 morphants retained rhythmic heartbeat (Supplementary videos 3, 4). Second, dorsal aortic lumen defects were not observed in silent heart /tnnt2 morphants, which lack heartbeat and vascular ow (Supplementary Fig. 3a)33. Accordingly, both amotl2a and amotl2b were required for proper DA morphogenesis.
2 NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743 ARTICLE
a
Brightfield Tg (kdrl:EGFP)s843;Tg (gata1:dsRed)sd2
DA
PCV
amotl2b MOCtrl
amotl2a MO
amotl2 MO
b
Ctrl
amotl2a MO amotl2b MO amotl2 MO
DA
PCV
DA PCV
DA PCV
c d
e
80
80
MO
hAMOTL2 mRNA
Embryos no/defective
circulation (%)
Embryos no/defective
circulation (%)
Embryos no/defective
circulation (%)
80 70 60 50 40 30 20 10
0 Ctrl amotl2
MO amotl2
*** ***
70
70
60
*** ***
60
*** ***
50
50
40
40
30
30
20
20
10
10
MO hAMOTL2 mRNA
0 Ctrl amotl2a
amotl2a
0 Ctrl amotl2b amotl2b
+
DA PCV
+
hAMOTL2 mRNA
+
Figure 1 | AmotL2 depletion affects zebrash circulation. (a) Brighteld (left) and uorescent images (right) of 48 h.p.f. double transgenic embryos where red blood cells express dsRed (Tg(gata1:dsRed)sd2) and endothelial cells are visualized by EGFP (Tg(kdrl:EGFP)s843); control, amotl2a, amotl2b, and amotl2a/b (hereafter referred to as amotl2 MO) injected embryos (morphants). amotl2 morphants show loss of trunk circulation (arrowhead) and peri-yolk oedema (arrow), even though they have beating hearts. DA and PCV are marked with red and blue arrowheads, respectively (top panel). Scale bar, 100 mm.
(b) Magnied images (yellow box in a) show loss of dsRed-positive erythrocytes in the morphant ISVs and DA. DA morphogenesis is affected in amotL2 morphants, while the PCV is unaffected (brackets indicate vessel diameter). At 48 h.p.f., both the ISVs and dorsal anastomosing vessel were present, but lacked patent lumens. The lack of visible lumens in ISVs is due to the absence of blood ow in the aorta. Scale bar, 50 mm. (ce) Rescue of amotl2a (c), amotl2b (d) and amotl2 MO (e) defects by co-injection with full-length wild-type human amotL2 p100 mRNA demonstrating that the circulatory defects are specically caused by loss of amotl2 function. nZ60 embryos per group, ***Pr0.001 as calculated by the l2 test.
AmotL2 is required for endothelial elongation. The aortic lumen defects in amotl2 MO may have been caused by defective cell proliferation, cell morphogenesis or polarity. Cell counts showed no difference between the control and morphant aortic endothelium. We turned our attention to endothelial cell shape during aortic tube formation. By injecting a i1a:mCherry containing plasmid into Tg(i1a:EGFP) zebrash embryos, individual aortic endothelial cells were mosaically labelled with mCherry. In zebrash, aortic endothelia have a attened
and elongated morphology (Fig. 3a)34. The dimensions of individual mCherry-positive DA endothelial cells were quantied by calculating the length to width and the length to height ratios (bidirectional arrows, Fig. 3a). Quantication of these morphometric ratios showed a signicant defect in anteroposterior elongation in amotl2-depleted embryos (Fig. 3b,c). These morphological changes could be restored by co-injection with human AMOTL2 messenger RNA (mRNA) (Fig. 3a,b,c).
NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications 3
& 2014 Macmillan Publishers Limited. All rights reserved.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743
a
Tg (fli1a:EGFP)y1
Tg (fli1a:EGFP)y1
DA
PCV
DA
PCV
* *
Ctrl amotl2b MO amotl2a/b MO
amotl2a MO
Figure 2 | DA lumen constrictions in amotl2 MO morphants. (a) Transverse sections (left, thickness 200 mm) from 48 h.p.f. Tg(i1a:EGFP)y1 sh stained with phalloidin (red) to image F-actin and TO-PRO-3 iodide (blue) to label nuclei. In close up (mid panel), control embryos show a patent DA lumen (red asterisk) and a patent PCV lumen (blue asterisk). Scale bar, 10 mm. Luminal DA constrictions are present in amotl2a, amotl2b and amotl2 MO morphants (arrowheads). The appearance of a midline aorta in amotl2 MO indicated that midline directed migration was unaffected. Sagittal views (right) of the DA (red brackets show vessel diameter) and PCV (blue brackets show vessel diameter) in controland amotl2 morphants. amotl2 morphants show DA constrictions(red arrowheads) and reduced DA diameter. Scale bar, 50 mm.
AmotL2 regulates cytoskeletal organization. Next, we assessed whether the observed deciency in endothelial cell elongation was due to perturbations in cytoskeletal architecture. In order to study actin reorganization in real time, we used a transgenic sh expressing Lifeact (a 17-amino-acid peptide that binds to lamentous actin) fused to green uorescent protein (GFP)35. Vascular-specic expression of Lifeact-GFP was directed by the VE-cadherin promoter. In control sh, Lifeact signal was mainly localized to cortical junctional actin, as well as to radial actin bres connecting perpendicularly to endothelial junctions (Fig. 3d). Of particular interest, in amotl2 morphant Lifeact sh, these bres were disrupted and positive signals were detected in intracellular punctae instead (Fig. 3d). Lifeact signals associated with cortical actin were not detectably affected in amotl2 morphants (Fig. 3d). The actin bre network could be restored by reintroduction of human amotL2 mRNA (Fig. 3d). A similar actin lament defect was observed by phalloidin immunouorescence staining of zebrash embryos. (Supplementary Fig. 2b,c). Parallel analysis of tnnt2 morphants showed that endothelial cells maintained the cellular shape and the actin lament network also in the absence of circulation (Supplementary Fig. 3be). We therefore concluded that the amotL2 effect on endothelial morphogenesis was not an indirect effect of perturbed axial circulation.
We went on to assess whether the observed cytoskeletal phenotype was associated with defects in mislocalization of junctional proteins. VE-cadherin localization was analysed in live VE-cadherinEGFP transgenic sh as well as by whole mount
immunostaining using VE-cadherin-specic antibodies (Fig. 3e and Supplementary Fig. 4a). Both approaches showed junction localization of VE-cadherin even with the altered morphology of the amotl2 morphant aortic endothelial cells. This was also the case with the ZO1 tight junction marker (Supplementary Fig. 4b).
To assess apicalbasal cell polarity in morphant embryos, we also analysed the localization of apical podocalyxin and basement membrane laminin. In amotl2 MO, podocalyxin was observed in a seam-like pattern between paired endothelial cells of the morphant aortae, suggesting that apical polarity had been established and that membrane translocation of podocalyxin was not affected (Fig. 3f). Likewise, basement membrane anti-laminin staining was unaffected (Fig. 3g). Taken together, the in vivo experiments indicated a specic defect in the actin laments anchored in the cellular junctions, whereas junction formation and the establishment of apicalbasal polarity appeared intact.
Inactivation of amotL2 in mouse induces aortic constrictions. In order to further understand the role of amotL2, we used a genetic deletion approach to silence gene expression during mouse embryonic blood vessel development. We rst examined the expression patterns of amotL2 in vivo, by western blot analysis and whole mount immunouorescence staining of mouse embryos. A 100 kDa amotL2 band was detected in embryonic lysates from E5 to E19 (Supplementary Fig. 5a). Laser scanning confocal microscopy revealed positive amotL2 staining that localized to CD31-positive cellular junctions of the DAe of embryos at E8 (Fig. 4a). To inactivate the amotL2 gene in a cell type-specic fashion, we generated mice with loxP sites anking exon 3 (Supplementary Fig. 5b). The resulting amotL2lox/lox mice were then mated with Cdh5(PAC)-CreERT2 transgenics. The latter allowed efcient tamoxifen-inducible conditional recombinase expression in endothelial cells36. Tamoxifen-driven recombination was veried by genomic PCR analysis from embryonic and yolk sac extracts (Supplementary Fig. 5c).
At E9.5, amotL2Dlox/Dlox/Cdh5(PAC)-CreERT2 mice (from here on referred to as amotL2Dlox/Dlox) did not differ signicantly in size from Cre-negative littermates and were viable (Fig. 4b). Analysis of the vascular system of mutants at E9.5 showed that in 80% of mutant embryos, one or both aortae showed lumen defects (Fig. 5a). The activity of amotL2 appeared to be dose dependent, as we detected aortic phenotypes in amotL2 heterozygote embryos at similar frequencies (Fig. 5a). We also observed aortic constrictions close to the ventricular outow tract (Supplementary Fig. 5d), whereas no defects were detected in littermates that lacked the Cre gene. The efciency of tamoxifen injections in inducing Cre expression in the vasculature of embryos was monitored in vivo after mating to YFP-reporter mice (Fig. 5b). Here, YFP-positive areas (indicating amotl2 recombination) correlated with aortic constrictions (Fig. 5b) Similar to our observations in zebrash, endothelial cells of the aorta in amotL2-mutant mice exhibited a rounded cell shape (Fig. 5c). Other vascular beds such as the lumen of the PCV, ISVs and the brain vascular plexus were not seemingly affected. Furthermore, no detectable inhibition of postnatal retinal angiogenesis could be detected (Supplementary Fig. 6a,b).
amotL2 links VE-cadherin to junctional actin laments. In order to gain further insight into how amotL2 might regulate actin architecture, we downregulated amotL2 expression using small interfering RNAs (siRNAs) in cultured mammalian endothelial MS1 cells. amotL2 was located to areas where actin bres anchor in the VE-cadherin-positive endothelial junctions (Fig. 6a). In amotL2 siRNA-treated MS1 cells, VE-cadherin still
4 NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743 ARTICLE
a b
Tg (fli1a:EGFP)y1
c
Length to height ratio Length to width ratio
NS NS
**
12
Length to heigth ratio
***
6
Ctrl amotl2 MO
DA
DA
DA
10
5
4
8
MO
Length to width ratio
3
6
2
4
1
2
MO
0 Ctrl amotl2
amotL2
MO
0 Ctrl amotl2
amotl2
amotl2 MO +
hAMOTL2
mRNA
hAMOTL2 mRNA
+
hAMOTL2
+
mRNA
d
Tg (cdh5:gal4)mu101 ;Tg (UAS:lifeact-GFP)mu271
e
Tg(fliep:GFF)ubs3, (UAS:mRFP), (UAS:VE-cadherinC-EGFP)ubs12
Ctrl amotl2 MO
DA
DA
DA
Ctrl amotl2 MO
DA
f
Tg (fli1a:EGFP)y1,
anti-podocalyxin
g
Tg (fli1a:EGFP)y1,
anti-laminin
XZ
XZ
DA
DA
DA
DA
Ctrl
Ctrl
amotl2MO +
hAMOTL2
mRNA
amotl2 MO
amotl2 MO
DA
Figure 3 | Aortic endothelial cell shape and cytoskeletal defects in amotl2 MO. (a) Sagittal (left) and dorsal (right) view of a mCherry-labelled DA endothelial cell of a 30 h.p.f. zebrash embryo. Images show three-dimensional surface reconstruction of individual mCherry-expressing cells withinthe DA. Bidirectional arrows indicate the length and width dimensions. In amotl2 MO, DA endothelial cells show altered cell shape. These morphological changes as well as the lumen defect can be reversed by injection of a human amotL2 mRNA. Scale bar, 10 mm. (b) Quantication of length to width ratio in individual mCherry positive, control and amotl2 MO aortic endothelial cells, as well as amotl2 MO cells rescued by co-injection with human amotL2 mRNA (control n 18 cells, amotl2 MO n 10 cells, amotl2 MO hAMOTL2 mRNA n 11 cells, Ctrl versus amotL2 MO P 0.011, Ctrl versus amotL2
MO hamotL2 mRNA P 0.541. (c) Quantication of length to height ratio in individual mCherry positive, control and amotl2 MO aortic endothelial cells
(Ctrl versus amotL2 MO P 0.0003, Ctrl versus amotL2 MO hamotL2 mRNA P 0.722). P-values were calculated by students t-test. Error bars indicate
s.d. NS, non signicant. (d) Endothelial actin cytoskeletal structure visualized in the dorsal aortic endothelia from living 48 h.p.f. Tg(cdh5:gal4)mu101;
Tg(UAS:lifeact-GFP)mu271 transgenic sh. Red boxes indicate magnied areas (right). Arrowheads show actin laments present in the control, and punctuate actin in the amotl2 MO. Arrows indicate cortical actin present in both control and amotl2 MO embryos. By introducing human amotL2 mRNA, actin laments could be restored (arrowheads). Scale bar 10 mm. (e) In control Tg(iep:GFF)ubs3; (UAS:mRFP); (UAS:VE-cadherinDC-EGFP)ubs12embryos (top), where VE-cadherin is tagged to EGFP, and endothelial cells labelled by mRFP, VE-cadherin enmarks cellcell junctions. In amotL2 MO embryos (bottom),
VE-cadherin is still localized in between endothelia at sites of aortic constrictions. Boxed areas are magnied to the right, VE-cadherinEGFP signal indicated with arrowheads. Scale bar 10 mm. (f) The apical-membrane sialomucin podocalyxin (arrowheads) is retained in apical membranes of amotl2
MO DA constrictions. Control Tg(i1a:EGFP)y1 28 h.p.f. embryos (top) and amotl2 MO (bottom). Boxed areas are magnied below. This is also visualized in the optical transverse section (XZ, right). Scale bar, 10 mm. (g) In control Tg(i1a:EGFP)y1 28 h.p.f. embryos (top), anti-laminin staining is basal (arrowheads) and in amotl2 MO, anti-laminin staining is unaffected (arrowheads, bottom). Scale bar, 10 mm.
showed junctional expression, but the connection to actin bres was lost (Fig. 6a,b). Strikingly, amotL2-depleted cells did not form actin laments that connect to the cellcell junctions whereas cortical actin was maintained (Fig. 6a,b), consistent with the zebrash amotl2 MO phenotype (Fig. 3d).
The integrity of VE-cadherin-based adherens junctions is calcium dependent and can be modulated by withdrawal and subsequent re-addition of calcium37. Re-addition of calcium to
calcium-depleted MS1 cells resulted in synchronous cell shape changes correlating with formation of actin laments associated to endothelial junctions (Supplementary Fig. 7b). In contrast, knockdown of amotL2 in MS1 cells rendered the cells refractory to calcium-induced cell shape changes (Fig. 6c). In addition, in ctrl siRNA MS1 cells, calcium re-addition caused relocalization of VE-cadherin and amotL2 from the cytoplasm to cell junctions with similar kinetics (Supplementary Fig. 7b).
NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications 5
& 2014 Macmillan Publishers Limited. All rights reserved.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743
a
amotL2 CD31 amotL2/CD31
DA DA DA
DA
DA
b
CD31
CD31
CD31/TO-PRO-3
amotL2lox/lox ,Cre
* *
CD31
CD31
CD31/TO-PRO-3
amotL2lox/lox ,Cre+
Figure 4 | Genetic deletion of Amotl2 in mice results in aortic lumen constrictions. (a) amotL2 immunouorescence staining (green) was detected at cellcell junctions in aortic endothelial cells of mouse embryos (E8), and colocalized to CD31 staining (red). Scale bar, 10 mm. (b) CD31 staining visualized the blood vessel network of a amotL2lox/lox, Cre embryo (E9.5). The magnied image (mid panel), showed presence of a DA lumen (bracket marks vessel diameter). The existence of lumens in the paired dorsal aortae was also apparent in the transverse vibratome section (asterisk, 150 mm thickness, right panel). Endothelial cells were labelled with CD31 (green) and TO-PRO-3 was used to visualize nuclei (blue). In somite staged amotL2Dlox/Dlox,
Cre embryos (E9.5), the general vascular network was present, but in the magnied image (mid panel), it was evident that the lumen of the DA was constricted. This could also be observed in the transverse vibratome section (arrowhead, 150 mm thickness, right panel). Scale bar, 100 mm.
We and others have shown that the Amot family of proteins associates to the scaffold junctional protein MAGI1 via a WW protein interaction motif38,39. It has further been reported that MAGI1 associates to VE-cadherin via binding to b-catenin40,41.
These ndings raised the question whether amotL2 functions together with VE-cadherin in controlling cytoskeletal architecture. Therefore, we performed co-immunoprecipitation of amotL2 and associated proteins before and after re-addition of calcium. As shown in Fig. 6d, VE-cadherin, MAGI1, b-catenin, a-catenin and b-actin were pulled down together with amotL2 in MS1 endothelial cells. Of interest, amotL2 association with b-actin correlated with actin bre formation and cell elongation (Fig. 6d).
Analysis of the amotL2/VE-cadherin complex. We further analysed the biochemical composition of the VE-cadherin/ amotL2 complex. To this end, we mutated the putative WW-binding motifs located in the N-terminal domain of amotL2, by exchanging the tyrosine to an alanine (Fig. 7a). Co-immunoprecipitation analysis showed that the LPTY but not the PPQY motif was required for the association to MAGI1 and b-actin, while neither of the sites were important for the binding to VE-cadherin or b-catenin (Fig. 7b). The importance of the LPTY site was further underscored by functional analysis in zebrash. mRNA encoding wt, LPTA or PPQA-mutant human
amotL2 were co-injected with amotL2 morpholinos into zebrash embryos as described in previous sections. Mutation of the LPTY motif completely abrogated the rescue effect of the injected mRNA while the PPQA mutant rescued the circulatory phenotype to the same extent as the wild-type mRNA (Fig. 7c). As shown in Fig. 7d, MAGI1 could be co-immunoprecipitated together with amotL2 and VE-cadherin. However, the binding of MAGI1 to VE-cadherin was lost in amotL2 siRNA-depleted cells. These data suggested that amotL2 coupled MAGI1 and actin bres to the VE-cadherin junctional complex. We next used amotL2 deletion constructs (shown in Fig. 7a) to narrow down the sequences essential for the association with VE-cadherin. Co-immunoprecipitation analysis localized the VE-cadherin and b-catenin binding site to the 101-307a.a. of the N-terminal domain of amotL2 (Fig. 7e).
amotL2 mediates mechanical force at cellular junctions. Our data showed that amotL2 linked VE-cadherin to actin bres that were coupled perpendicular to cellular junctions. The recent evidence that cadherinprotein complexes are sites of mechanotransduction raised the possibility that amotL2 integrated actomyosin contractile forces, required for lumen expansion17. First, we assessed whether chemical inhibition of actin contraction using the non-muscle myosin inhibitor blebbistatin could phenocopy the effect of amotl2 MO in zebrash.
6 NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743 ARTICLE
a
b CD31 GFP
amotL2lox/lox
DA
100
***
***
NS
Cre;YFP/
aortic constriction (%)
80
Embryos with
60
DA
40
20
*
0 wt/wt or Cre
wt/lox, Cre+
lox/lox, Cre+
amotL2lox/lox
Cre+;YFP+/
*
c
amotL2lox/lox, Cre
amotL2lox/lox, Cre+
CD31/TO-PRO-3
* * *
*
Figure 5 | amotL2 KO induces aortic constrictions and altered endothelial cell shape. (a) Quantication of aortic defects showed presence of aortic constrictions in around 80% of both amotL2wt/Dlox, Cre and amotL2Dlox/Dlox, Cre embryos. All embryos lacking Cre-recombinase expression, as well as amotL2wt/wt, Cre embryos were considered wt and grouped together. n(amotL2wt/wt or Cre ) 10 embryos, n(amotL2wt/Dlox, Cre ) 11 embryos,
n(amotL2Dlox/Dlox, Cre ) 19 embryos). NS, non signicant, P-values were calculated by the l2 test. (b) GFP immunouorescence staining was performed
to visualize the YFP reporter, as a marker for Cre-recombinase expression. GFP expression (green) colocalized to CD31 staining (red), in vasculatureof E8.5 embryos, arguing for specic expression of GFP in cells expressing CDH5-Cre-recombinase. Constriction of the DA was observed in areas of GFP-positive endothelial cells. Boxed areas are magnied to the right. Aortas of control embryos show a patent lumen (bracket), while in amotL2Dlox/Dlox
embryos, the aorta is constricted (asterisk). Scale bar 100 mm. (c) Magnied images from vibratome sections of an amotL2lox/lox, Cre , as well as three examples of amotL2Dlox/Dlox Cre embryos. Images of the latter showed altered shape of aortic endothelial cells, as visualized by CD31 staining (green). Control endothelial cells showed elongated and at morphology, compared with the short and rounded shape of the endothelial cells from the amotL2Dlox/Dlox embryo. TO-PRO-3 was used for labelling the nuclei (blue). Asterisks indicate DA lumen. Scale bar 10 mm.
In agreement with amotl2 MO, blebbistatin treatment between 1820 h.p.f. caused loss of circulation and reduced length to width and length to height ratios in mCherry-labelled dorsal aortic endothelia in vivo and in MS1 cells in vitro (Fig. 8ad, Supplementary Fig. 8a,e,f). Furthermore, actomyosin contractility appeared essential for the maintenance of lumen expansion, as treatment of embryos after initiation of axial vessel circulation induced collapse of the DA (Supplementary Fig. 8d). Taken together, these data supported the notion that contractile mechanical forces were required for aortic luminal expansion.
The striking effect of amotL2 depletion on the junctional actin lament organization suggested a role in mediating the mechanical load on cellular adhesions. To test this hypothesis, we employed traction force microscopy to measure tension between pairs of endothelial cells. This method has been described by Gardel and coworkers19 and the junctional force is indirectly calculated by measuring forces exerted on the extracellular matrix42. Control or amotL2 siRNA-depleted MS1 cells were plated on bronectin, which had been chemically cross-linked to polyacrylamide gels. Forces applied on the cellextracellular matrix interface were quantied by measuring the displacement of uorescent beads before and after removal of cells by trypsinization. The force transmitted between doublets of cells was determined using a calculation of the imbalance of traction forces exerted on the focal adhesions (Fig. 8e,f)19. The net force exercised on the junctions was signicantly lower in the amotL2-depleted cells (Fig. 8f,i). In addition, in control cells,
forces were directed perpendicular to the cell junctions, whereas the directional force was lost in the amotL2 siRNA-treated cells (Fig. 8g,h). A schematic is shown in Fig. 9a showing how force is transmitted via endothelial adherent junctions through the VE-cadherin/amotL2 complex leading to the expansion of the aortic lumen (Fig. 9b).
DiscussionA major issue in the vascular development is how individual endothelial cells collectively unite in the formation of tubes. How do endothelia interpret, integrate and translate multiple cues into dened, reproducible cytoskeletal architectures and multicellular organization structures? In this report, we provide mechanistic insight into how mechanical force via cellcell adhesions and the cytoskeletal network coordinate aortic lumen expansion. This process involves the protein amotL2 that links the generation of VE-cadherin-associated contractile actin laments to cell and tissue morphogenesis.
Endothelial cells elongate in the anteriorposterior axis during aorta formation. In our studies, we could show that this cellular shape change was not dependent on the shear stress exerted by blood ow. Instead, we propose that endothelial morphogenesis during aortic lumen formation is dependent on the tensile forces exerted via the VE-cadherin/amotL2 junctional complex. This notion was supported by our ndings that short-term treatment with the myosin inhibitor blebbistatin mimicked the effects of
NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications 7
& 2014 Macmillan Publishers Limited. All rights reserved.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743
a b
amotL2 VE-cadherin F-Actin
F-Actin/TO-PRO-3 VE-cadherin/TO-PRO-3
ZO-1/TO-PRO-3
cell1 cell1 cell1
cell2 cell2 cell2
cell1 cell1 cell1
cell2 cell2 cell2
0 0 1 2 3 4 5 6 Hours after restoration of Ca2+
Ctrl siRNA amotL2 siRNA
Ctrl siRNA amotL2 siRNA
IP: IgG, Ca2+
IP: IgG, +Ca2+
c
d
IP: amotL2
Hours after restoration of Ca
0 1 2 3 6 8
IB: amotL2 100 kDa
100 kDa
6
Length to width ratio
5
7 *** ******
NS
*
4
Ctrl siRNA
AmotL2 siRNA
IB: VE-cadherin
IB: -catenin
IB: -Actin
Lysate
100 kDa
90 kDa
42 kDa
3
2
IB: -catenin
100 kDa
1
IB: MAGI1
Figure 6 | AmotL2 is associated with the VE-cadherinprotein complex. (a) Phalloidin staining visualized axial actin bres (grey) that insert into the anti-VE-cadherin-positive endothelial adherens junctions (green). amotL2 (red) colocalized with actin bres where they insert into the junction between the apposed endothelial surfaces (arrowheads). Yellow line indicates the cellcell interface. When amotL2 levels were depleted by siRNA, VE-cadherin was still present at cellcell junctions, but its connection to actin bres were lost. (b) In MileSven1 pancreatic islet endothelial (MS1) cells, F-actin bres were visualized with phalloidin staining (red) (magnied in box to the lower right, arrowhead). Actin bres were absent in amotL2 siRNA-treated cells, but cortical actin belts were still present. The adherens and tight junction-associated proteins, VE-cadherin and ZO-1 (green) were still present at cellcell contacts in amotL2 siRNA-treated MS1 cells. Scale bar, 10 mm. (c) Calcium switch time course experiment showing that reformation of VE-cadherin-based adherens junctions with calcium induces cell elongation as measured by progressively increasing length to width ratio in control siRNA-treated MS1 cells.
amotL2 siRNA-treated MS1 cells did not elongate even after re-addition of calcium. n445 cells per group. P(0h) 0.017, P(1h) 0.494,
P(2h) 1.443 10 13, P(3h) 1.306 10 25, P(6h) 1.694 10 34. P-values were calculated by the students t-test. Error bars indicate s.d.
NS, nonsignicant. (d) Co-immunoprecipitation of amotL2 followed by western blot analysis at different time points after re-addition of Ca2 . The association of the VE-cadherin/catenin complex to amotL2 was independent of calcium levels. On the contrary, MAGI1 and b-Actin only associated to the VE-cadherin/catenin/amotL2 complex after restoration of calcium levels.
amotL2 depletion. In addition, we could show that amotL2 was essential for the transmission of junctional force between endothelial cells in vitro. This nding is signicant, as it shows how amotL2 enables the formation of transcellular actin cables that share mechanical actin and tension in between cells. Further, this allows lumen expansion to become a collective event that is needed for the synchronization with the onset of circulation.
It was apparent that amotL2 inactivation specically affected aortic function, whereas the vein lumen formation appeared to be intact. The mechanisms of how these two tubular structures are formed may provide an explanation for this. Similar to epithelial lumen formation in vitro, the aortic lumen is generated between adjacent endothelial cells by establishment of apicalbasal polarity and the subsequent repulsion and expansion requires accumulation of uid pressure and actin contraction. There are other principles described for the development of large calibre vessels such as the common cardinal vein. Here, lumen is formed by ensheathment of preexisting luminal space35. Inherent differences in the mechanisms of lumen formation may therefore explain why amotL2 is essential for aortic and not vein lumen
formation. We did notice a slight delay in ISV formation in amotL2 MO embryos; however, no detectable difference was observed compared with control embryos at 48 h.p.f. Furthermore, inactivation of amotL2 during postnatal retinal angiogenesis did not affect endothelial cell migration. An indirect effect on ISV formation, due to defects in the DA, may therefore explain the apparent discrepancies between our data and what has previously been reported43.
VE-cadherin has previously been shown to be essential for multiple biological processes that inuence endothelial cells, such as proliferation, migration, permeability and polarity44. Our data show that amotL2 is a downstream effector of VE-cadherin controlling cell elongation and junctional force. We propose a model, whereby amotL2 integrates VE-cadherin junctional signalling to endothelial actin bre assembly during DA lumen expansion (Fig. 9). This may occur in conjunction with other cellular mechanisms for lumen expansion, like electrostatic repulsion and vectoral uid transport45,46. Taken together, we have identied a novel mechanism by which force can be transmitted across cells via adherens junctions and actin bres. Further studies may show whether the connection between
8 NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743 ARTICLE
a
Human AMOTL2 ENST00000422605
L P T Y107 P P Q Y213
N C
314375
420509
545
572
1780
1100
1307
101307
581780
b
IP: amotL2
c
Untransfected
***
NS
1.2 ***
Embryos with no
circulation
amotL2
LPTA/PPQA
PPQA
LPTA
1.0
VE-cadherin
-catenin
Ctrl IgG
(relative ratio)
0.8
100 kDa
90 kDa
100 kDa
42 kDa
0.6
0.4
0.2
MAGI1
-Actin
0.0
amotL2 MO + + + +
hAMOTL2
mRNA
hAMOTL2 LPTA
hAMOTL2 PPQA
d e
MS1 Lysate
Control siRNA amotL2 siRNA
IB: amotL2
IB: -Actin
+
+
1780
581780 aa
1307 aa
1100 aa
101307
IB: VE-cadherin
IB: -catenin
IP: MAGI1
+
+
IB: MAGI1
IB: -catenin
100 kDa
100 kDa
90 kDa 100 kDa
42 kDa
100 kDa IP: Myc-tag
Lysate
IB: VE-cadherin
IB: -catenin
IB: Myc-tag
Untransfected
100 kDa 100 kDa
100 kDa
37 kDa
Figure 7 | AmotL2 association with VE-cadherin controls actin bre formation in vitro. (a) Schematic model showing the different domains of the human amotL2 protein (ensembl accession code ENST00000422605). Putative coilcoil domains (314375, 420509, 545572), carboxy-terminal PDZ-binding motif and the amino-terminal LPTY (107) and PPQY (213) WW-binding sites. In addition, the different amotL2 deletion constructs used are shown. (b) Endogenous amotL2, as well as the wild-type construct co-immunoprecipitates with VE-cadherin, b-catenin, a-catenin, MAGI1 and b-Actin and in MS1 cells. Mutation of the PPQY motif did not affect the binding to the VE-cadherin adherens junction complex. When the LPTY motif was mutated to
LPTA, the binding of amotL2 to MAGI1 and b-Actin was lost. The double mutant (LPTA/PPQA) showed a binding efciency similar to the LPTA mutation alone. (c) The amotL2 MO circulatory phenotype in 48 h.p.f. zebrash embryos could be rescued by injection of the wild-type human amotL2 mRNA, and the mRNA with a mutation in the PPQY motif. The LPTA-mutant mRNA did not restore circulation. n(amotL2 MO) 215 embryos, n(amotL2 MO hamotL2
mRNA) 193 embryos, n(amotL2 MO hamotL2 LPTA mRNA) 84 embryos, n(amotL2 MO hamotL2 PPQY mRNA) 181 embryos. NS, nonsignifcant.
P-values were calculated by the l2 test. (d) When immunoprecipitation was performed after silencing of amotL2 expression by siRNA, MAGI1 association to the VE-cadherin/catenin protein complex was abrogated. In addition, the binding of MAGI1 to b-Actin was lost. (e) Full-length amotL2-Myc (1780 aa)
or the indicated Myc-tagged amotL2 deletion constructs were transfected into MS1 cells. amotL2 was immunoprecipitated from cell lysates using anti-Myc antibody. Only constructs containing the 101307 aa domain was able to interact with VE-cadherin and b-catenin.
amotL2, adherens junctions, and the actin network is a unifying principle in lumen formation in tubular epithelial and ductal organs.
Methods
Mouse experiments. Animal experiments were performed according to a permit from the Stockholm South ethical committee in Sweden. The amotL2 conditional knockout mice were crossed with Cdh5(PAC)CreERT2 as well as ROSA26EYFP reporter mice. All the animals were in C57BL/6 background. Mouse tail tips, yolk sacs or embryos were used for genotyping. The primers used in genomic PCR are as follows:
for amotL2 ox gene: 50-CTAGGAGCACGTGGAAGACC-30 (forward)
50-GGGCTAGCTGCTCTACAAGG-30 (reversed); for amotL2 deox gene: 50-CAGGAGGATCACACCACCAG-30 (forward)
50-CAGCAAG TGGAAAGCCTGAG-30 (reversed).
To investigate the function of amotL2 during mouse embryonic development, tamoxifen was intraperitoneally injected into pregnant amotL2lox/lox/Cdh5(PAC) CreERT2/ROSA26EYFP mice from E5.5 to E8.5. The dose of tamoxifen was0.5 mg for E5.5 and 1.0 mg per day for the remaining 3 days. Embryos were collected at E9.5 and xed with 4% paraformaldehyde (PFA).
To analyse the function of amotL2 during postnatal retina angiogenesis, intragastric injection with tamoxifen (50 mg per day from P1 to P3) was performed on amotL2lox/lox/Cdh5(PAC)CreERT2/ROSA26EYFP male and female pups47. Mouse retinas were dissected at P6 and xed with PFA for immunostaining.
Zebrash. Zebrash were raised and maintained according to the standard protocols and in accordance with the regulations set out by the Swedish Board of Agriculture for the use of laboratory animals in scientic research. The following transgenic lines were used in this study:
Tg(kdrl:EGFP)s843 (ref. 34); Tg(gata1:dsRed)sd2 (ref. 48);
NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications 9
& 2014 Macmillan Publishers Limited. All rights reserved.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743
a
Tg (fli1a:EGFP)y1
b
c d
Length to height ratio Length to width ratio
**
Embryos with
heartbeat but no
circulation (%)
100
80 60 40 20
0
12
***
Ctrl
***
Length to width
ratio
6 5 4 3 2 1 0
Length to height
ratio
10
8
6
4
2
0
Ctrl
Blebbistatin
5 M
DA
DA
Blebbistatin
5 M
Blebbistatin
5 M
Blebbistatin
5 M
Ctrl
Ctrl
e
g h
Ctrl siRNA amotL2 siRNA
Cellcell force (%)
Cellcell force (%)
60
020
2040
60
020
2040
4060
6080
40
40
20
f
20
Traction magnitude
Nanobeads/Force vectors
0
0
500
300
4060
6080
80100
100120
120140
140160
80100
100120
120140
140160
Cellcell force angle, [afii9835]
400
Ctrl siRNA AmotL2 siRNA
Cell 1 Cell 2
Cellcell force angle, [afii9835]
200
i
100
200
Cellcell force (nN)
***
0
300
150
100
200
Cell 1
Cell 2
50
100
0 Ctrl siRNA
amotL2 siRNA
0
Figure 8 | AmotL2 is required for generation of actomyosin dependent cellcell force. (a) Zebrash embryos treated with 5 mM of the actomyosin-inhibiting drug blebbistatin, during aortic lumen formation (1820 h.p.f.) show defective circulation at 30 h.p.f. Sagittal (left) and dorsal (right), view of individual mCherry-positive DA endothelial cells in the Tg(i1a:EGFP)y1 embryos (30 h.p.f.). Bidirectional arrows indicate the length and width dimensions. In blebbistatin-treated embryos, DA endothelial cells have altered cell shape. Scale bar 10 mm. (b) Quantication of the circulatory phenotype in blebbistatin-treated embryos (n(ctrl) 57 embryos, n(blebbistatin) 121 embryos, P-value calculated by the l2 test). (c) Quantication of length to width
ratio in dorsal aortic endothelia from blebbistatin-treated zebrash embryos (control n 18 cells, blebbistatin treated n 11 cells, P 1.8 10 3).
(d) Quantication of length to height ratio in aortic endothelia from blebbistatin-treated zebrash embryos (P 3.8 10 5). P-values calculated by the
students t-test. (e) Illustration of the traction force microscopy experiment. MS1 cellcell doublets were seeded onto hydrogel-embedded uorescent beads (green). As the cells produce force, the consequent movement of the beads was used to calculate both the cell traction force (red arrows) and further the cellcell force (black arrows) with Fourier Transform Traction Cytometry. (f) Traction stress magnitudes of a cell doublet (left). Grey line indicate the outline of the cells and the bold white line the region of the cellcell junction used to calculate the force imbalance within the cell doublet. Stresses are given in Pascal. The images were divided into 10 10 squares and the resultant traction vector of each square was calculated (magnitude and angle) and
presented (right, black arrows) superimposed with GFP-tagged nanobeads (200 nm, grey). Black lines indicate cell borders. For original image of traction vectors see Supplementary Fig. 5h. (g,h) Histogram presenting quantication of the angles between the cellcell force and the cellcell contact in the shown cell doublets. Pattern of force angle distribution between ctrl siRNA and amotL2 siRNA cell doublets was signicantly different. KS 0.35,
P 9.29 10 5. P-value was calculated by the KolmogorovSmirnov test. (i) Scatter plot of the cellcell force comparing ctrl siRNA-treated MS1 cell
doublet (n 54, means.d. is 5529 nN) and amotL2 siRNA-treated MS1 cell doublet (n 45, means.d. is 3719 nN), P-value was calculated by the
students t-test.
Tg(i1a:EGFP)y1 (ref. 49); Tg(kdrl:msna-EGFP)is1 (ref. 50); Tg(cdh5:gal4)mu101 (ref. 51);Tg(UAS:lifeact-GFP)mu271;Tg(iep:GFF)ubs3;
Tg(UAS:mRFP); Tg(UAS:VE-cadherinDC-EGFP)ubs12 (ref. 52).
For vascular-specic expression of lifeact-GFP double transgenic embryos Tg(cdh5:gal4)mu101; Tg(UAS:lifeact-GFP)mu271 were used, which we refer to in the text as Lifeact sh35.
Expression analysis. Paralogue-specic epitopes were chosen for the production of anti-amotL2a antibodies. Afnity-puried rabbit polyclonal antibodies against the zebrash amotL2a protein were made using the antibody production services of Innovagen (Lund, Sweden). For amotL2a, antibodies were made against the C-terminal epitope NH2- CQKAPSAVDLFKGVDDVSAE-COOH.
Total RNAs were isolated by RNeasy Kit (Qiagen), according to the manufacturers instructions. Each sample was reverse-transcribed into cDNAby miScript RT Kit (Qiagen) and was subjected to quantitative real time (qRT)PCR analysis with miScript SYBR Green PCR Kit (Qiagen). The following oligonucleotides were used:
amotl2a f1 50-GGGCACTTTATGCTCAACTCTTG-30 amotl2a r1 50-CGGCCTTGCTCTCGTCTT-30 amotl2b f1 50-CGCCCTTCAGCGAAGTTATTC-30 amotl2b r1 50-CCCGCACAACGTGACAATG-30
Mouse amotL2 was detected with a rabbit afnity-puried antibody made against the C-terminal motif of human amotL2 (Innovagen, Lund, Sweden); NH2-CLDSVATSRVQDLSDMVEILI-COOH.
Western blotting. Dechorionated zebrash embryos were mechanically homogenized in SDS sample buffer, after removal of the yolk, and loaded onto 10%
10 NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743 ARTICLE
Junctional force
a b
Control
amotl2 KO
VE-cadherin
-catenin MAGI1
amotL2 F-Actin
Figure 9 | Proposed model of the function of the VE-cadherin/AmotL2 complex during aortic lumen expansion. (a) AmotL2 is needed for the connection of the VE-cadherin/catenin complex to MAGI1 and actin laments, and for transmission of force between neighbouring cells via the cellular junctions. (b) amotL2 knockdown results in perturbed lumen expansion or collapse of the DA. The DA is made of elongated and at endothelial cells that are connected by actin bres (shown as yellow spikes). Actin bres insert into the apposing endothelial adherens junctions (yellow borders), and enables transcellular transmission of mechanical force, and thus endothelial elongation. In amotL2 KD animals, polarized endothelia (apical membranes are shown in blue) lack radial actin bres, resulting in failed cell morphogenesis and luminal constrictions.
Bis-Tris gel. Cells were lysed with Triton X-100 before samples were loaded onto the gel. The following antibodies were used: anti-VE-cadherin (1:500, #555289, 11D4.1, BD Biosciences), anti-b-catenin (1:500, #610154, 14/beta-catenin,
BD Biosciences), anti-a-catenin (1:500, #610193, 5/alpha-catenin, BD Biosciences), anti-MAGI1 (1:500, #WH0009223M3, 7B4, Sigma), anti-b-actin (1:20000, #ab3280, ALTN05CC4, Abcam). The mouse embryo E5-E19 western blot was ordered from Zyagen and amotL2 was detected with a rabbit afnity-puried antibody against the C-terminal motif of human amotL2; NH2-CLDSVATSRVQ DLSDMVEILI-COOH (1:500). Uncropped scans of the western blots are provided as Supplementary Figs 912.
Cloning of zebrash amotl2a and amotl2b genes. Database searches on Ensembl and NCBI with hAMOTL2 identied two amotl2 orthologues in the zebrash genome. The sequence of amotl2a has previously been published32. To verify the putative amotl2b sequence, the complete gene was cloned and sequenced from a cDNA zebrash library isolated from 48 h.p.f. embryos. amotl2a sequences were cloned by real-time PCR using the following primers and TOPO cloned into pCRII (Invitrogen) using the following primers:
amotl2a forward 50-ATGAGAACGGCAGAGGAATC-30 amotl2a reverse 50-TGGACATTGTTATCTCAGATG-30 amotl2b f1 50-ACCAGGTGGACTACCAGCA-30 amotl2b r1 50-GTTCCTGCTCTAGCCGTGTC-30 amotl2b f2 50-GGAGAAGGCCCTCAAAATTC-30 amotl2b r2 50-AGCTCCGTTATTGAGCTGGA-30
Morpholino knockdown experiments. Morpholinos were purchased from Gene Tools (Philomath, Oregon, USA). The following morpholinos were used in this study:
amotl2a MO 50-CTGATGATTCCTCTGCCGTTCTCAT-30 amotl2b MO1 50-TGAGTATTTATGATCTGAGCTGAAC-30 amotl2b MO2 50-TGAGTATTTATGATCTGAGCTGAAC-30 amotl2b MO3 50-AGCTGAGTCAGTGTACCTTCTGAAT-30 tnnt2 50-CATGTTTGCTCTGATCTGACACGCA-30control 50-CCTCTTACCTCAGTTACAATTTATA-30
The tnnt2 morpholino has been published33. The amotl2a morpholino was injected at 1.25 ng per embryo and the amotl2b morpholino was injected at 2.5 ng per embryo. Morpholino-injected zebrash embryos were maintained at 28 C in standard E3 water supplemented with 0.003% phenyl-2-thiourea. Gene knockdown was conrmed molecularly by RTPCR (amotl2b) or western blot (amotl2a). Circulation phenotypes were assessed at 48 h.p.f. An mRNA encoding human AMOTL2 or amotL2 mutants were synthesized using the SP6 Message Machine kit (Ambion, Austin, TX, USA), and 50 pg per embryo were co-injected together with the morpholinos.
For imaging individual endothelial cells, the Tol2 construct pDEST (i1:mCherryCAAX) was co-injected with Tol2 mRNA into newly fertilized embryos and DA cells were imaged at 28 h.p.f. following standard protocols53. Briey, the vector pDEST (i1:mCherryCAAX) containing Tol2 transposon sequences was co-injected (25 ng ml 1) with Tol2 mRNA (35 ng ml 1). The Tol2 mRNA was produced by in vitro transcription using mMessage mMachine Kit SP6 (#1340, Ambion). The mixture was injected into one-cell-stage embryos. At
28 h.p.f. embryos were dechorinated and mounted in 1% low-melt agarose on a coverslip for imaging of mCherry-expressing DA cells.
Pharmacological experiments. Pharmacological experiments with 10 mM cytochalasin D or 50 mM ROCK inhibitor Y-27632 (Sigma) were used to inhibit F-actin polymerization in zebrash embryos from 1828 h.p.f. For blebbistatin experiments, zebrash embryos were treated with 5 mM blebbistatin from1820 h.p.f. and then moved to drug-free egg water for recovery. MS1 (Mile Sven1 pancreatic endothelial cells, ATCC CRL-2279) were treated with 5 mM blebbistatin for 2 h, whereupon they were washed with fresh medium.
siRNA transfection. For siRNA transfections, cells were seeded the day before transfection on glass slides (BD Falcon Cultureslides BD Biosciences) coated with 1% BD Matrigel Basement Membrane Matrix (BD Biosciences) in growth medium without antibiotics. Just before transfection, growth medium was exchanged for OPTI-MEM I Reduced Serum Media (Invitrogen). Smartpool siGENOME siRNAs (Dharmacon/Thermo Scientic) against amotL2 (M-062016-01), as well as non-targeting siRNA Pool #2 (D-001206-14) were transfected into the cells with Oligofectamine Transfection Reagent (Invitrogen) according to the manufacturers protocol. siRNAs were used at the nal concentrations of 0.32 mM for both control and amotL2 siRNAs. Four hours after transfection serum was added to a nal concentration of 20%. Cells were allowed to grow for 72 h prior to the evaluation by immunouorescence staining or western blot.
Cytoo chip experiments. Control and amotL2 siRNA-treated MS1 cells were seeded on starter bronectin-coated Cytoo chips (10-900-10-26, France) and allowed to grow for 3 h. Cells were then xed in 4% PFA and stained with anti-paxillin and phalloidin (TexasRed-X Phalloidin # T7471, Invitrogen).
Calcium switch assay. 30,000 cells per well were seeded onto glass slides (BD Falcon Cultureslides BD Biosciences) coated with 1.5% gelatin. Cells were allowed to attach and spread over night. The following day transfection with controland amotL2 siRNA was performed, as described previously. Two days after transfection, medium was changed to calcium-free medium. Twenty-two hours later cells were put back into normal growth medium (t 0h), and allowed to grow
for another 1, 2, 3 and 6 h respectively before xation.
Immunouorescence staining. Cells were washed in phosphate-buffered saline (PBS) and xed in 4% PFA for 10 min at room temperature (RT). After washing in PBS, permeabilization was performed with 0.1% Triton X-100 for one minute at RT. Cells were again washed in PBS and blocked for 1 h in 5% horse serum (HS) at RT. Antibodies were diluted in the blocking solution, and all incubations were performed at RT. Incubations were 1 h for primary antibodies and 45 min for secondary antibodies. The following antibodies and stains were used; anti-VE-cadherin (1:100, #555289, 11D4.1, BD Biosciences), anti-ZO-1 (1:200, #339100, ZO1-1A12, Invitrogen), anti-paxillin (1:100, #610620, 165/Paxillin, BD Biosciences), anti-laminin (1:200, #L9393, polyclonal, Sigma), TO-PRO-3 iodide (642/661) (1:1000, #T3605, Invitrogen) and phalloidin (1:200, TexasRed-X Phalloidin # T7471, Invitrogen)/Phalloidin-Atto647N (1:200, #65906, Sigma), AlexaFlour 488/568 secondary antibodies (1:1000, Invitrogen).
NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications 11
& 2014 Macmillan Publishers Limited. All rights reserved.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743
Zebrash embryos were xed in 4% PFA/PBS at 4 C overnight and processed for whole mount immunouorescence staining following standard protocols. Rabbit antibodies against zebrash podocalyxin and VE-cadherin/Cdh-5 have been previously published54,55. For anti-VE-cadherin staining, embryos were xed in 2% PFA/PBS/0.1% Tween20. Alternatively, 48 h.p.f. Tg(i1a:EGFP)y1 zebrash embryos were xed, sectioned on a Leica Vibratome in 4% low-melt agarose at a thickness of 200 mm. Sections were stained with TexasRed-X Phalloidin for visualizing F-actin and TO-PRO-3 iodide for labelling the nuclei. Images were taken on a Zeiss LSM700 Confocal/Zeiss LSM5 Exciter confocal microscope and processed using ImageJ. Images of endothelial cells expressing mCherryCAAX under the i1a promoter were processed with Imaris (Bitplane) to create a three-dimensional surface. Images of phalloidin and podocalyxin staining of Tg(i1a:EGFP)y1 embryos were processed with Imaris (Bitplane) to minimize nonendothelial signal. This was performed by creating a new co-localization channel, showing only the podocalyxin positive pixels that also are positive for EGFP.
Mouse embryos (E8 or E9.5) were xed in 4% PFA at 4 C, overnight (O/N).
Next day embryos were washed with PBS and permeabilized with 0.2% Triton X-100 in PBS at RT. Blocking was performed in 5% HS/0.1% Triton X-100/PBS at
4 C, O/N. Embryos were washed with 5% HS/0.1% Tween20/PBS before incubation with primary antibody in the same buffer at 4 C, O/N. After the
antibody incubation, embryos were washed rst with 5%HS/0.1%Tween20/PBS at
4 C, and second with 0.1% Tween20 at 4 C. After washing, embryos were
exposed to a second xation in 4%PFA for one hour at 4 C. Thereafter, another
washing was performed in 0.1%Tween20 in PBS. Secondary antibody incubation was performed as for the primary antibody. On the last day, embryos were washed in 0.1%Tween20 in PBS at 4 C, xed again in 4%PFA for 1 hat 4 C, and
washed in 0.1%Tween20 in PBS at 4 C. Embryos were mounted on coverslips
with ProLong Gold anti-fade reagent (#P36930, Invitrogen). For visualization of blood vessels anti-CD31 (#550274, MEC13.3, BD Biosciences) and for conrmation of knock down anti-GFP (#ab6673, polyclonal, Abcam) antibodies were used.
For amotL2 staining in mouse aorta, embryos were rst sectioned sagittally with a Leica Vibratome in 4% low-melt agarose at a thickness of 350 mm; thereafter, staining and mounting was performed as described above.
Co-Immunoprecipitation. MS1 endothelial cell lysate were immunoprecipitated with anti-amotL2 polyclonal antibodies (reactive to human amotL2 C-terminal peptide, LDSVATSRVQDLSDMVEILI) or anti-Myc Tag (#05-724, 4A6, Millipore). Immunocomplexes bound to protein A Sepharose beads were gently washedve times with lysis buffer (50 mM HEPES buffer, pH 7.4, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1 mM EGTA and protease inhibitors) and separated by SDS-PAGE. amotL2 binding proteins were detected by western blot.
Traction force microscopy. Polyacrylamide gels were prepared as previously described56. Briey, an acrylamide solution containing 6.67% acrylamide and0.167% bisacrylamide was mixed with uorescent beads by sonication before the addition of APS and TEMED. For imaging, an Eclipse Ti inverted microscope (Nikon) with a 60 oil immersion objective (Nikon 60 1.4 NA) and a Neo
sCMOS camera (Andor Technology) was used. Two images of the beads, before and after cell doublet detachment, and one bright eld image of the cell doublet were recorded. The global shift between the beads was determined by cross-correlation of the images. Cell detachment was performed with trypsin (Gibco).
The method used for force calculations on continuous substrates was described previously57. Briey, the force exerted by cell1 on cell2 is given by:
~F1=2
Xcell1~ Ti
" #after X
cell1
~
Statistical analysis. For zebrash experiments, over 60 larvae were analysed per condition. This gave 80% power to detect a 20% difference with 95% condence. For mouse experiments, 10 embryos were assigned per group. This sample size gave 80% power to detect a 50% phenotypic difference with 95% condence. For categorical qualitative analysis l2 test was used and for quantitative data evaluation two-tailed students t-test was performed. Pattern distribution was analysed with KolmogorovSmirnov test.
References
1. Herbert, S. P. & Stainier, D. Y. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 12, 551564 (2011).
2. Strilic, B. et al. The molecular basis of vascular lumen formation in the developing mouse aorta. Dev. Cell 17, 505515 (2009).
3. Xu, K. & Cleaver, O. Tubulogenesis during blood vessel formation. Semin. Cell Dev. Biol. 22, 9931004 (2011).
4. Zeeb, M., Strilic, B. & Lammert, E. Resolving cell-cell junctions: lumen formation in blood vessels. Curr. Opin. Cell Biol. 22, 626632 (2010).
5. Iruela-Arispe, M. L. & Davis, G. E. Cellular and molecular mechanisms of vascular lumen formation. Dev. Cell. 16, 222231 (2009).
6. Axnick, A., J. & Lammert, E. Vascular lumen formation. Curr. Opin. Hematol. 19, 192198 (2012).
7. Davis, G. E. & Senger, D. R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 97, 10931107 (2005).
8. Carmeliet, P. et al. Targeted deciency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98, 147157 (1999).
9. Gory-Faure, S. et al. Role of vascular endothelial-cadherin in vascular morphogenesis. Development 126, 20932102 (1999).
10. Xu, K. et al. Blood vessel tubulogenesis requires Rasip1 regulation of GTPase signaling. Dev. Cell 20, 526539 (2011).
11. Zovein, A. C. et al. Beta1 integrin establishes endothelial cell polarity and arteriolar lumen formation via a Par3-dependent mechanism. Dev. Cell 18, 3951 (2010).
12. Chung, A. S. & Ferrara, N. Developmental and pathological angiogenesis. Ann. Rev. Cell Dev. Biol. 27, 563584 (2011).
13. Eilken, H. M. & Adams, R. H. Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr. Opin. Cell Biol. 22, 617625 (2010).
14. De Smet, F., Segura, I., De Bock, K., Hohensinner, P. J. & Carmeliet, P. Mechanisms of vessel branching: lopodia on endothelial tip cells lead the way. Arterioscler. Thromb. Vasc. Biol. 29, 639649 (2009).
15. Lohela, M., Bry, M., Tammela, T. & Alitalo, K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 21, 154165 (2009).
16. Ingber, D. E. Tensegrity and mechanotransduction. J. Bodyw. Mov. Ther. 12, 198200 (2008).
17. Leckband, D. E., le Duc, Q., Wang, N. & de Rooij, J. Mechanotransduction at cadherin-mediated adhesions. Curr Opin. Cell Biol. 23, 523530 (2011).
18. Liu, Z. et al. Mechanical tugging force regulates the size of cell-cell junctions. Proc. Natl Acad. Sci. USA 107, 99449949 (2010).
19. Maruthamuthu, V., Sabass, B., Schwarz, U. S. & Gardel, M. L. Cell-ECM traction force modulates endogenous tension at cell-cell contacts. Proc. Natl Acad. Sci. USA 108, 47084713 (2011).
20. Borghi, N. et al. E-cadherin is under constitutive actomyosin-generated tension that is increased at cell-cell contacts upon externally applied stretch. Proc. Natl Acad. Sci. USA 109, 1256812573 (2012).
21. Dejana, E., Orsenigo, F. & Lampugnani, M. G. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J. Cell Sci. 121, 21152122 (2008).
22. Harris, E. S. & Nelson, W. J. VE-cadherin: at the front, center, and sides of endothelial cell organization and function. Curr. Opin. Cell Biol. 22, 651658 (2010).
23. Montero-Balaguer, M. et al. Stable vascular connections and remodeling require full expression of VE-cadherin in zebrash embryos. PloS One 4, e5772 (2009).
24. Millan, J. et al. Adherens junctions connect stress bres between adjacent endothelial cells. BMC Biol. 8, 11 (2010).
25. Nelson, W. J., Drees, F. & Yamada, S. Interaction of cadherin with the actin cytoskeleton. Novartis Found. Symp. 269, 159168; discussion 168-177, 223-130 (2005).
26. Huveneers, S. et al. Vinculin associates with endothelial VE-cadherin junctions to control force-dependent remodeling. J. Cell Biol. 196, 641652 (2012).
27. Bratt, A. et al. Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene 298, 6977 (2002).
28. Aase, K. et al. Angiomotin regulates endothelial cell migration during embryonic angiogenesis. Genes Dev. 21, 20552068 (2007).
Ti" #before
1
A similar expression is used to obtain the force ~F2=1 exerted by cell2 on cell1. These two forces should be opposite with the same magnitude (the discrepancy between them is used as an estimation of the error on the cellcell force value). The average tension at the cellcell interface is estimated by:
~Fcell-cell
~F1=2
~F2=1
=2:
2
The uorescent beads were tracked to obtain a displacement eld with high spatial resolution. Using a combination of particle imaging velocimetry and particle tracking, the nal displacement eld is obtained on a regular grid using linear interpolation. Forces were reconstructed using Fourier transform traction cytometry with zeroth-order regularization, and the cell contractile strength could be estimated by calculating the strain energy U (forces multiplied by displacements), which represents the total energy transferred from the cell to the elastic distortion of the substrate. The force transmitted at a single cellcell contact between doublets of cells was determined by calculating the balance of traction forces exerted on the extracellular matrix as previously introduced19. All calculations and image processing were performed in Matlab. For clearer visibility of force vectors, the images were divided into 10 10 squares with a grid. The
resultant vector (magnitude and angle) of each square was calculated and presented in Fig. 7 (Original force vectors are shown in Supplementary Fig. 5).
12 NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4743 ARTICLE
29. Ernkvist, M. et al. The Amot/Patj/Syx signaling complex spatially controls RhoA GTPase activity in migrating endothelial cells. Blood 113, 244253 (2009).
30. Zheng, Y. et al. Angiomotin-like protein 1 controls endothelial polarityand junction stability during sprouting angiogenesis. Circ. Res. 105, 260270 (2009).
31. Ernkvist, M. et al. p130-angiomotin associates to actin and controls endothelial cell shape. FEBS J. 273, 20002011 (2006).
32. Huang, H. et al. amotL2 is essential for cell movements in zebrash embryo and regulates c-Src translocation. Dev. 134, 979988 (2007).
33. Sehnert, A. J. et al. Cardiac troponin T is essential in sarcomere assembly and cardiac contractility. Nat. Genet. 31, 106110 (2002).
34. Jin, S. W., Beis, D., Mitchell, T., Chen, J. N. & Stainier, D. Y. Cellular and molecular analyses of vascular tube and lumen formation in zebrash. Development 132, 51995209 (2005).
35. Helker, H., C. S. et al. The zebrash common cardinal veins develop by a novel mechanism: lumen ensheathment. Development 140, 27762786 (2013).36. Nakayama, N., M. et al. Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat. Cell Biol. 15, 249260 (2013).
37. Schnittler, H. J., Puschel, B. & Drenckhahn, D. Role of cadherins and plakoglobin in interendothelial adhesion under resting conditions and shear stress. Am. J. Physiol. 273, H2396H2405 (1997).
38. Bratt, A. et al. Angiomotin regulates endothelial cell-cell junctions and cell motility. J. Biol. Chem. 280, 3485934869 (2005).
39. Patrie, K. M. Identication and characterization of a novel tight junction-associated family of proteins that interacts with a WW domain of MAGI-1. Biochim. Biophys. Acta 1745, 131144 (2005).
40. Sakurai, A. et al. MAGI-1 is required for Rap1 activation upon cell-cell contact and for enhancement of vascular endothelial cadherin-mediated cell adhesion. Mol. Biol. Cell 17, 966976 (2006).
41. Dobrosotskaya, I. Y. & James, G. L. MAGI-1 interacts with beta-catenin and is associated with cell-cell adhesion structures. Biochem. Biophys. Res. Commun. 270, 903909 (2000).
42. Dembo, M. & Wang, Y. L. Stresses at the cell-to-substrate interface during locomotion of broblasts. Biophys. J. 76, 23072316 (1999).
43. Wang, Y. et al. Angiomotin-like2 gene (amotl2) is required for migration and proliferation of endothelial cells during angiogenesis. J. Biol. Chem. 286, 4109541104 (2011).
44. Dejana, E. & Vestweber, D. The role of VE-cadherin in vascular morphogenesis and permeability control. Prog. Mol. Biol. Transl. Sci. 116, 119144 (2013).
45. Bagnat, M., Cheung, I. D., Mostov, K. E. & Stainier, D. Y. Genetic control of single lumen formation in the zebrash gut. Nat. Cell Biol. 9, 954960 (2007).
46. Strilic, B. et al. Electrostatic cell-surface repulsion initiates lumen formation in developing blood vessels. Curr. Biol. 20, 20032009 (2010).
47. Pitulescu, M. E., Schmidt, I., Benedito, R. & Adams, R. H. Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice. Nat. Protoc. 5, 15181534 (2010).
48. Traver, D. et al. Transplantation and in vivo imaging of multilineage engraftment in zebrash bloodless mutants. Nat. Immunol. 4, 12381246 (2003).
49. Lawson, N. D. & Weinstein, B. M. In vivo imaging of embryonic vascular development using transgenic zebrash. Dev. Biol. 248, 307318 (2002).
50. Wang, Y. et al. Moesin1 and Ve-cadherin are required in endothelial cells during in vivo tubulogenesis. Development 137, 31193128 (2010).
51. Bussmann, J., Wolfe, S. A. & Siekmann, A. F. Arterial-venous network formation during brain vascularization involves hemodynamic regulation of chemokine signaling. Development 138, 17171726 (2011).
52. Lenard, A. et al. In vivo analysis reveals a highly stereotypic morphogenetic pathway of vascular anastomosis. Dev Cell 25, 492506 (2013).
53. Fisher, S. et al. Evaluating the biological relevance of putative enhancers using Tol2 transposon-mediated transgenesis in zebrash. Nat. Protoc. 1, 12971305 (2006).
54. Blum, Y. et al. Complex cell rearrangements during intersegmental vessel sprouting and vessel fusion in the zebrash embryo. Dev. Biol. 316, 312322 (2008).
55. Herwig, L. et al. Distinct cellular mechanisms of blood vessel fusion in the zebrash embryo. Curr. Biol. 21, 19421948 (2011).
56. Tseng, Q. et al. A new micropatterning method of soft substrates reveals that different tumorigenic signals can promote or reduce cell contraction levels. Lab Chip 11, 22312240 (2011).
57. Butler, J. P., Tolic-Norrelykke, I. M., Fabry, B. & Fredberg, J. J. Traction elds, moments, and strain energy that cells exert on their surroundings. Am. J. Physiol. Cell Physiol. 282, C595C605 (2002).
Acknowledgements
This work has been supported by grants from the Swedish Cancer Society, Swedish Research Council, Cancer Society of Stockholm. C.H. and W.H. were funded by the NRW return fellowship. We would like to thank Jeffrey Essner for the Tg(kdrl:msna-EGFP)is1 transgenic line and Stefan Schulte-Merker for the double transgenic sh Tg(kdrl:EGFP)s843; Tg(gata1:dsRed)sd2 transgenic line. We are indebted to Dannel McCollum for sharing amotL2 constructs. Thanks to the Karolinska sh facility for providing embryos and raising sh strains. We thank the Knut and Alice Wallenberg Foundation (CLICK) and the Uppsala SciLife BioVis bio-imaging facility for providing microscopy facilities. Thanks to Bertrand Joseph for supportive discussions. We are grateful to Mattias Karln for help with graphics.
Author contributions
L.H. S.H. and A.M. designed the experiments and wrote the manuscript. S.H., S.V. and A.M. performed the zebrash experiments and whole mount stainings as well as confocal imaging. Y.Z. performed the mouse amotL2 KO and Co-IP experiments. M.M. performed in vitro analysis of cell shape and cytoskeleton. M.B. and R.M. designed and performed the traction force microscopy. H.-G.B. and M.A. contributed the VE-cadherin transgenic zebrash and PDXL antibodies. R.H.A. contributed the cdh5(PAC)ERCre transgenic mouse, W.H. and S.M.H. contributed the Tg(cdh5:gal4)mu101; Tg(UAS:lifeact-GFP)mu271, transgenic zebrash. P.U. helped with confocal imaging. All authors discussed the results and commented on the manuscript.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications
Competing nancial interests: The authors declare no competing nancial interests.
Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/
How to cite this article: Hultin, S. et al. amotL2 links VE-cadherin to contractile actin bres necessary for aortic lumen expansion. Nat. Commun. 5:3743 doi: 10.1038/ ncomms4743 (2014).
NATURE COMMUNICATIONS | 5:3743 | DOI: 10.1038/ncomms4743 | www.nature.com/naturecommunications 13
& 2014 Macmillan Publishers Limited. All rights reserved.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright Nature Publishing Group May 2014
Abstract
The assembly of individual endothelial cells into multicellular tubes is a complex morphogenetic event in vascular development. Extracellular matrix cues and cell-cell junctional communication are fundamental to tube formation. Together they determine the shape of endothelial cells and the tubular structures that they ultimately form. Little is known regarding how mechanical signals are transmitted between cells to control cell shape changes during morphogenesis. Here we provide evidence that the scaffold protein amotL2 is needed for aortic vessel lumen expansion. Using gene inactivation strategies in zebrafish, mouse and endothelial cell culture systems, we show that amotL2 associates to the VE-cadherin adhesion complex where it couples adherens junctions to contractile actin fibres. Inactivation of amotL2 dissociates VE-cadherin from cytoskeletal tensile forces that affect endothelial cell shape. We propose that the VE-cadherin/amotL2 complex is responsible for transmitting mechanical force between endothelial cells for the coordination of cellular morphogenesis consistent with aortic lumen expansion and function.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer